CLINICAL TRIALS PROFILE FOR ESTRAMUSTINE PHOSPHATE SODIUM

All Clinical Trials for Estramustine Phosphate Sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002721 ↗	Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer	Completed	University of New Mexico	Phase 1	1995-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.
NCT00002775 ↗	Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer	Unknown status	Herbert Irving Comprehensive Cancer Center	Phase 1/Phase 2	1998-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	M.D. Anderson Cancer Center	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00003066 ↗	Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer	Unknown status	Herbert Irving Comprehensive Cancer Center	Phase 2	1997-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of docetaxel combined with estramustine in treating women with metastatic breast cancer.
NCT00003084 ↗	Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.
NCT00003084 ↗	Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer	Completed	M.D. Anderson Cancer Center	Phase 2	1997-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.

Clinical Trial Conditions for Estramustine Phosphate Sodium

Condition Name

Condition Name for Estramustine Phosphate Sodium
Intervention	Trials
Prostate Cancer	26
Adenocarcinoma of the Prostate	2
Lymphoma	2
Stage IV Prostate Cancer	1

Condition MeSH

Condition MeSH for Estramustine Phosphate Sodium
Intervention	Trials
Prostatic Neoplasms	27
Lymphoma	2
Adenocarcinoma	2
Thromboembolism	1

Clinical Trial Locations for Estramustine Phosphate Sodium

Trials by Country

Trials by Country for Estramustine Phosphate Sodium
Location	Trials
United States	219
Canada	3
Puerto Rico	2
Australia	1
South Africa	1

Trials by US State

Trials by US State for Estramustine Phosphate Sodium
Location	Trials
New York	16
Illinois	10
Ohio	8
New Jersey	8
Michigan	8

Clinical Trial Progress for Estramustine Phosphate Sodium

Clinical Trial Phase

Clinical Trial Phase for Estramustine Phosphate Sodium
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	17
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for Estramustine Phosphate Sodium
Clinical Trial Phase	Trials
Completed	23
Unknown status	4
Terminated	2

Clinical Trial Sponsors for Estramustine Phosphate Sodium

Sponsor Name

Sponsor Name for Estramustine Phosphate Sodium
Sponsor	Trials
National Cancer Institute (NCI)	21
Eastern Cooperative Oncology Group	4
Herbert Irving Comprehensive Cancer Center	3

Sponsor Type

Sponsor Type for Estramustine Phosphate Sodium
Sponsor	Trials
Other	39
NIH	22
Industry	2